Anticancer effect and enhanced chemotherapy potential of resveratrol in human pancreatic cancer cell lines ⁎

Author:

Chen Sumei1,Zhang Ke1,Chen Yuanyuan1,Zheng Ruzhen1,Zhao Penjun1,Zhu Jianwei2,Wu Shuming3,Deng Qinghua14,Ma Shenglin14,Xiong Guangsu3

Affiliation:

1. Department of Radiation Oncology, Hangzhou Cancer Hospital, Hangzhou 310002, China

2. Department of Oncology, Hangzhou Cancer Hospital, Hangzhou 310002, China

3. Division of Gastroenterology and Hepatology, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai 200001, China

4. Affiliated Hangzhou First People’s Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China

Abstract

AbstractObjectiveGemcitabine, the only approved drug for the treatment of pancreatic cancer, is not very effective. Novel and effective cancer chemopreventive agents are urgently needed. Recently, emerging studies determined resveratrol possessed anticancer effects on various cancer cells. We explored the anticancer effect of resveratrol in pancreatic cancer cells and investigated the involved moleculars of action. We also examined whether resveratrol enhanced antitumor activity of gemcitabinein vitro.MethodsProliferation inhibition was assessed by cell count kit-8 assay. Cell cycle phase distribution and apoptotic cells were measured by flow cytometric analysis. We determined the expression of bcl-2, cyclinD1, and activation of caspases-3 and poly (ADP-ribose) polymerase1 proteins used Western blot analysis.ResultsResveratrol inhibited the proliferation of three pancreatic cancer cell lines in a dose dependent fashion, and induced accumulation of cells at the G1 phase as well as apoptosis. Our data also demonstrated that resveratrol enhanced gemcitabine-induced apoptosis in pancreatic cancer cells. In addition, resveratrol inhibited the expression of cyclinD1, bcl-2, and induced activation of caspase-3 and poly (ADP-ribose) polymerase1.ConclusionOur results suggested that resveratrol might be not only a potential regimen, but also an effective chemosensitizer for the chemotherapy of pancreatic cancer.

Publisher

Ovid Technologies (Wolters Kluwer Health)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3